Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Morphic (MORF) Stock Forecast & Price Target

Morphic logo
Get the Latest News and Ratings for MORF and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Morphic and its competitors.

Sign Up

MORF Analyst Ratings Over Time

TypeCurrent Forecast
12/22/23 to 12/21/24
1 Month Ago
11/22/23 to 11/21/24
3 Months Ago
9/23/23 to 9/22/24
1 Year Ago
12/22/22 to 12/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
5 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$57.00$54.25$54.25$59.75
Forecasted Upside0.02% Upside-4.81% Downside-4.81% Downside106.75% Upside
Consensus Rating
Hold
Hold
Hold
Moderate Buy

MORF Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MORF Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Morphic Stock vs. The Competition

TypeMorphicMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.81
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside0.02% Upside25,828.65% Upside14.54% Upside
News Sentiment Rating
Neutral News

See Recent MORF News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/26/2024Royal Bank of Canada
4 of 5 stars
G. Renza
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$57.00 ➝ $57.00+0.72%
7/22/2024Stifel Nicolaus
4 of 5 stars
 Boost TargetHold ➝ Hold$30.00 ➝ $57.00+0.85%
7/9/2024TD Cowen
5 of 5 stars
R. Baral
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
7/9/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Seigerman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$52.00 ➝ $57.00+2.30%
12/8/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$46.00+73.00%
10/16/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
9/25/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
7/21/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$75.00+31.05%
4/25/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$67.00 ➝ $80.00+76.17%
3/8/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$45.00 ➝ $56.00+22.70%
3/8/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$45.00 ➝ $56.00+22.70%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:44 PM ET.


MORF Forecast - Frequently Asked Questions

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Morphic is $57.00, with a high forecast of $57.00 and a low forecast of $57.00.

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Morphic in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MORF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MORF, but not buy additional shares or sell existing shares.

According to analysts, Morphic's stock has a predicted upside of 0.02% based on their 12-month stock forecasts.

Analysts like Morphic less than other "medical" companies. The consensus rating for Morphic is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MORF compares to other companies.


This page (NASDAQ:MORF) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners